NCT00328549View on ClinicalTrials.gov

A Study to Evaluate the Erythropoietic Response in Hepatitis C Virus (HCV) Patients Receiving Combination Ribavirin (RBV)/Interferon (IFN) Therapy or RBV/PEG IFN (NATURAL HISTORY-HCV)

PHASE2CompletedINTERVENTIONAL
Enrollment

105

Participants

Timeline

Start Date

October 31, 2001

Study Completion Date

December 31, 2002

Conditions
Hepatitis CAnemia
Interventions
DRUG

Pegylated Interferon and Ribavirin

All Listed Sponsors
lead

Ortho Biotech Products, L.P.

INDUSTRY

NCT00328549 - A Study to Evaluate the Erythropoietic Response in Hepatitis C Virus (HCV) Patients Receiving Combination Ribavirin (RBV)/Interferon (IFN) Therapy or RBV/PEG IFN (NATURAL HISTORY-HCV) | Biotech Hunter | Biotech Hunter